It is very uncertain whether buprenorphine changes mean peak withdrawal score, compared with alpha2‐adrenergic agonists (very low certainty).
Buprenorphine showed no clear difference in mean overall withdrawal score, with various methods of assessment compared with alpha2‐adrenergic agonists (moderate certainty).
Buprenorphine probably leads to higher mean days in treatment (with varying scheduled duration) compared with alpha2‐adrenergic agonists (moderate certainty).
It is very uncertain whether buprenorphine changes number experiencing adverse effects compared with alpha2‐adrenergic agonists (very low certainty).
Buprenorphine showed no clear difference in number with treatment stopped due to adverse effects compared with alpha2‐adrenergic agonists (low certainty).
Buprenorphine probably leads to higher number completing withdrawal treatment compared with alpha2‐adrenergic agonists (moderate certainty).